Eisai (4523) Panoramica del titolo
Eisai Co., Ltd. si occupa di ricerca e sviluppo, produzione, vendita, importazione ed esportazione di prodotti farmaceutici in Giappone. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 4/6 |
4523 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% sottovalutato sconto intrinseco
5419.8%Revenue growth p.a.
6.2k
18
0
126
Concorrenti di Eisai Co., Ltd.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | JP¥4,687.00 |
| Massimo di 52 settimane | JP¥5,349.00 |
| Minimo di 52 settimane | JP¥3,659.00 |
| Beta | -0.10 |
| Variazione di 1 mese | -3.78% |
| Variazione a 3 mesi | 8.72% |
| Variazione di 1 anno | 12.91% |
| Variazione a 3 anni | -41.16% |
| Variazione a 5 anni | -34.93% |
| Variazione dall'IPO | 187.80% |
Notizie e aggiornamenti recenti
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).
4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook
Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).Recent updates
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook
Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).4523: Future Alzheimer Dosing Filings Will Still Not Support Current Valuation
Analysts have kept their ¥3,600 price target on Eisai steady, pointing to slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a lower assumed future P/E as the key drivers behind the updated view. What's in the News The U.S. FDA has granted Priority Review to Eisai's supplemental Biologics License Application for Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease, with a PDUFA action date set for May 24, 2026 (Key Developments).4523: Future Alzheimer Dosing Submissions Will Not Justify Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600 per share. They cite updated assumptions for slightly higher revenue growth and profit margins, alongside a more conservative future P/E.
4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Margins And Future Share Returns
Analysts have kept their Eisai price target steady at ¥6,200. The latest update reflects slightly softer revenue growth expectations at 7.31%, a modestly higher profit margin outlook of 11.14%, and a small adjustment in assumed future P/E to 18.03x.Eisai's (TSE:4523) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 17
Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Feb 11Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Feb 094523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns
Analysts have lifted their fair value estimate for Eisai to ¥6,200 from ¥6,000, citing updated assumptions that combine a slightly higher discount rate and lower revenue growth with a stronger projected profit margin and a lower future P/E multiple. What's in the News Eisai and BioArctic submitted a Marketing Authorisation Variation to the European Medicines Agency for once every four weeks IV maintenance dosing of lecanemab, following an initial once every two weeks regimen for 18 months in early Alzheimer’s disease.Eisai's (TSE:4523) Dividend Will Be ¥80.00
Jan 264523: Long-Term Alzheimer Injection Shift Will Not Sustain Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600.0, highlighting modest adjustments to revenue growth, profit margins and future P/E assumptions as they fine tune their price targets rather than rethink the core thesis. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous Leqembi autoinjector for early Alzheimer's treatment, with similar filings submitted to the U.S. FDA and Japan's PMDA, targeting at home weekly dosing as an alternative to current IV regimens (Key Developments).4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price
Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jan 064523: Future Alzheimer Data Will Not Justify Current Share Price
Analysts have raised their price target on Eisai to 3,600.00, reflecting improved expectations for revenue growth and slightly stronger profit margins, despite a modest uptick in the assumed discount rate and a marginally lower future P/E multiple. What's in the News New long term data for Alzheimer therapy Leqembi suggest early and continued lecanemab treatment could delay progression from mild cognitive impairment to moderate Alzheimer disease by up to 8.3 years, which supports sustained use and earlier initiation (CTAD conference presentations).4523: Future Alzheimer’s Pipeline And At Home Treatments Will Support Steady Outlook
Analysts have slightly reduced their price target on Eisai, trimming fair value by about $15 per share to approximately $5,012. They cited marginally lower long term growth and profitability assumptions, while maintaining a similar forward earnings multiple.Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Dec 034523: Upcoming Clinical Data And Regulatory Milestones Will Support Steady Long-Term Outlook
Analysts have maintained their price target for Eisai at ¥5,026.92, citing only minor adjustments to revenue growth and profit margin estimates. These adjustments did not significantly influence their overall valuation.Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Nov 19Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 094523: Upcoming Regulatory Approvals And Product Launches Will Drive Shares Higher
Narrative Update on Eisai: Analyst Price Target Revision Analysts have maintained their price target for Eisai at ¥5,026.92, citing slightly stronger revised revenue growth forecasts and a modest increase in the discount rate as underlying factors in their valuation assessment. What's in the News Health Canada issued a Notice of Compliance with conditions for LEQEMBI® (lecanemab), making it the first treatment for early Alzheimer's disease that targets an underlying cause to be authorized in Canada.Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
Narrative Update on Eisai Analysts have raised Eisai’s price target modestly from ¥4,988 to ¥5,027. This change reflects slight improvements in revenue growth and profit margin assumptions.Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Analysts have increased their price target for Eisai from ¥4,857.69 to ¥4,988.46. They cite slightly improved profit margin forecasts despite marginally lower expectations for revenue growth.Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Sep 22Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
The upward revision in the analyst price target for Eisai reflects a modest improvement in consensus revenue growth forecasts, now at 3.9% per annum, supporting the new fair value of ¥4858. What's in the News Eisai expanded its Canadian headquarters in Mississauga, increasing staff by 246% since 2020, demonstrating a firm commitment to R&D and healthcare innovation in Canada.Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Sep 08Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Eisai's consensus price target saw a marginal increase to ¥4,592, reflecting a slight improvement in revenue growth forecasts, while profit margins remained stable. What's in the News Eisai and Biogen launched LEQEMBI (lecanemab) in Austria and plan to launch in Germany, following EC approval as the first Alzheimer's disease therapy targeting both amyloid plaque and protofibrils, reducing clinical decline by 31% at 18 months versus placebo in the EU indicated population.Eisai's (TSE:4523) Dividend Will Be ¥80.00
Aug 25Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 08Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Jul 23Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jul 09Eisai's (TSE:4523) Solid Profits Have Weak Fundamentals
Jun 22Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results
May 18Rendimenti per gli azionisti
| 4523 | JP Pharmaceuticals | JP Mercato | |
|---|---|---|---|
| 7D | -1.1% | -4.3% | 0.2% |
| 1Y | 12.9% | 10.4% | 38.0% |
Ritorno vs Industria: 4523 ha trovato corrispondenza nel JP Pharmaceuticals che ha restituito 10.4 % nell'ultimo anno.
Rendimento vs Mercato: 4523 ha avuto una performance inferiore al mercato JP che ha registrato un rendimento 38 % nell'ultimo anno.
Volatilità dei prezzi
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.5% |
| 10% least volatile stocks in JP Market | 2.4% |
Prezzo delle azioni stabile: 4523 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato JP.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 4523 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1941 | 10,917 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. si occupa di ricerca e sviluppo, produzione, vendita, importazione ed esportazione di prodotti farmaceutici in Giappone. Offre Dayvigo, per il trattamento dell'insonnia; Lenvima, un agente antitumorale/medicinale a bersaglio molecolare per il trattamento del cancro alla tiroide, del carcinoma a cellule renali in combinazione con everolimus e del carcinoma epatocellulare; Methycobal per il trattamento della neuropatia periferica; Halaven, un agente antitumorale per il trattamento del cancro al seno. L'azienda fornisce anche Jyseleca, un inibitore della janus chinasi; Elental, un preparato a base di aminoacidi a catena ramificata; Goofice e Movicol per la stipsi cronica; Fycompa, un agente antiepilettico; Pariet, un inibitore della pompa protonica; Aricept, per il morbo di Alzheimer/demenza a corpi di Lewy; e Chocola BB plus per il preparato di vitamina B2.
Eisai Co., Ltd. Riepilogo dei fondamenti
| 4523 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | JP¥1.32t |
| Utili (TTM) | JP¥42.76b |
| Ricavi(TTM) | JP¥808.19b |
30.9x
Rapporto P/E1.6x
Rapporto P/S4523 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 4523 Conto economico (TTM) | |
|---|---|
| Ricavi | JP¥808.19b |
| Costo del fatturato | JP¥179.81b |
| Profitto lordo | JP¥628.38b |
| Altre spese | JP¥585.62b |
| Utili | JP¥42.76b |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 15, 2026
| Utile per azione (EPS) | 151.68 |
| Margine lordo | 77.75% |
| Margine di profitto netto | 5.29% |
| Rapporto debito/patrimonio netto | 25.2% |
Come si è comportato 4523 nel lungo periodo?
Vedi performance storica e confrontoDividendi
3.4%
Rendimento attuale del dividendo106%
Rapporto di remunerazione4523 paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di 4523| Eisai date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Mar 30 2026 |
| Data di pagamento dei dividendi | Jun 01 2026 |
| Giorni fino al dividendo Ex | 32 days |
| Giorni prima della data di pagamento dei dividendi | 31 days |
4523 paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di 4523Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/30 05:01 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Eisai Co., Ltd. è coperta da 21 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |